Mayo Clinic<\/a>, high triglycerides often accompany other cardiovascular risk factors, making effective management especially important.<\/p>\nWhy High Triglycerides Are Dangerous<\/h3>\n
High triglyceride levels are linked to serious health outcomes including atherosclerosis \u2014 the clogging and hardening of arteries that leads to heart attacks and strokes. Severe cases can trigger acute pancreatitis, a life threatening inflammation of the pancreas. Hypertriglyceridemia also frequently coexists with insulin resistance, forming a cycle that amplifies overall metabolic and cardiovascular risk.<\/p>\n
6 Key Insights From Hypertriglyceridemia Clinical Trials<\/h3>\n1. Niacin: Effective but Declining in Use<\/h4>\n
Niacin (vitamin B3) was the first drug approved to treat hyperlipidemia, available since approximately 1955. It works by inhibiting the liver’s production of VLDL, a precursor to LDL cholesterol, while also increasing HDL cholesterol levels.<\/p>\n
Hypertriglyceridemia clinical trials have shown niacin can reduce triglycerides by around 20% depending on dose. A notable study found that extended release niacin reduced LDL cholesterol more in women than men at all doses and reduced triglycerides at 1,500 mg. Despite these effects, niacin’s use has declined due to a lack of evidence linking it to reductions in cardiovascular events, alongside side effects including flushing, itching, and liver toxicity.<\/p>\n
2. Omega 3 Fatty Acids: Strong Evidence With Important Nuance<\/h4>\n
Prescription strength omega 3 products \u2014 particularly icosapent ethyl \u2014 can lower triglycerides by 25 to 30%. Hypertriglyceridemia clinical trials have produced mixed cardiovascular results depending on formulation and patient population.<\/p>\n
The REDUCE IT trial demonstrated a 25% reduction in major adverse cardiovascular events with icosapent ethyl. However, the OMEMI and STRENGTH trials, which tested different omega 3 formulations in elderly post myocardial infarction patients, found no significant cardiovascular benefit after two years, despite a triglyceride reduction of 8.1% in the omega 3 group. These findings underscore the importance of formulation and patient selection when applying trial data to clinical practice.<\/p>\n
3. Fibrates: Reliable Triglyceride Reduction With Monitoring Required<\/h4>\n
Fibrates including fenofibrate and gemfibrozil activate PPAR alpha, a protein that regulates lipid metabolism. This increases triglyceride breakdown and raises HDL cholesterol. Hypertriglyceridemia clinical trials consistently show triglyceride reductions of 30 to 50%, with the greatest benefit in patients with severe hypertriglyceridemia above 500 mg\/dL. Fibrates also reduce pancreatitis risk in very high triglyceride cases.<\/p>\n
Combining fibrates with statins requires careful monitoring due to increased muscle toxicity risk. Fenofibrate is generally preferred for its lower drug interaction profile.<\/p>\n
4. Volanesorsen: Breakthrough for Rare Genetic Cases<\/h4>\n
Volanesorsen is an antisense oligonucleotide that targets the APOC3 gene, suppressing a protein that inhibits triglyceride metabolism. Hypertriglyceridemia clinical trials for this agent have shown 70 to 80% triglyceride reductions in patients with familial chylomicronemia syndrome \u2014 a rare genetic condition. Its use is currently limited to these rare cases due to high cost, injection site reactions, and the need to monitor platelet counts regularly.<\/p>\n
5. Evinacumab: Emerging Biologic With Broad Potential<\/h4>\n
Evinacumab is a monoclonal antibody targeting angiopoietin like protein 3 (ANGPTL3), a regulator of triglyceride metabolism. Primarily approved for homozygous familial hypercholesterolemia, hypertriglyceridemia clinical trials have shown a 40 to 50% reduction in triglycerides in severely affected patients. High cost and intravenous administration remain barriers, but its potential role in broader lipid management is promising.<\/p>\n
6. Gene Therapy: The Long Term Horizon<\/h4>\n
Alipogene tiparvovec (Glybera) was the first gene therapy approved for a lipid disorder, targeting lipoprotein lipase deficiency \u2014 a rare genetic cause of severe hypertriglyceridemia. While it demonstrated triglyceride reductions and pancreatitis prevention in clinical trials, it was withdrawn from the market due to high cost and low demand. Emerging gene editing technologies like CRISPR may expand this approach significantly in the future.<\/p>\n
Lifestyle Modifications That Complement Drug Therapy<\/h3>\n
Hypertriglyceridemia clinical trials consistently show that pharmacological treatment works best when combined with lifestyle changes. Key interventions include:<\/p>\n
Dietary changes:<\/strong> Reducing refined carbohydrates and sugars, adding healthy unsaturated fats from avocados and olive oil, and incorporating marine based omega 3s from fatty fish like salmon and mackerel.<\/p>\nExercise:<\/strong> The American Heart Association recommends at least 150 minutes of moderate aerobic exercise per week. Walking, cycling, and swimming are among the most effective for improving triglyceride levels.<\/p>\nWeight management:<\/strong> Losing just 5 to 10% of body weight can significantly lower triglycerides, particularly in individuals with obesity.<\/p>\nAlcohol reduction:<\/strong> Even moderate alcohol intake can raise triglycerides in susceptible individuals.<\/p>\nJoin a Hypertriglyceridemia Clinical Trial at FOMAT<\/h3>\n
The search for even more effective triglyceride lowering treatments continues. At FOMAT, we actively support hypertriglyceridemia clinical trials across the United States, giving patients access to the latest therapies while advancing the research that shapes future care.<\/p>\n
Visit our Active Studies<\/a> page to explore current opportunities. Your participation could help define the next generation of triglyceride management.<\/p>\nSource: Triglyceride Lowering Drugs \u2014 Endotext, NCBI Bookshelf<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"Ensayos cl\u00ednicos sobre la hipertrigliceridemia: 6 hallazgos farmacol\u00f3gicos contrastados que marcan el rumbo del tratamiento Los ensayos cl\u00ednicos sobre la hipertrigliceridemia est\u00e1n aportando a los investigadores y m\u00e9dicos m\u00e1s informaci\u00f3n que nunca sobre c\u00f3mo controlar los niveles elevados de triglic\u00e9ridos y reducir los graves riesgos para la salud que estos conllevan. La hipertrigliceridemia se produce cuando los niveles de triglic\u00e9ridos superan\u2026<\/p>","protected":false},"author":3,"featured_media":87698,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[968],"tags":[],"class_list":["post-49661","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-blogs-updates"],"acf":[],"_links":{"self":[{"href":"https:\/\/fomatmedical.com\/es\/wp-json\/wp\/v2\/posts\/49661","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/fomatmedical.com\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/fomatmedical.com\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/fomatmedical.com\/es\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/fomatmedical.com\/es\/wp-json\/wp\/v2\/comments?post=49661"}],"version-history":[{"count":0,"href":"https:\/\/fomatmedical.com\/es\/wp-json\/wp\/v2\/posts\/49661\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/fomatmedical.com\/es\/wp-json\/wp\/v2\/media\/87698"}],"wp:attachment":[{"href":"https:\/\/fomatmedical.com\/es\/wp-json\/wp\/v2\/media?parent=49661"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/fomatmedical.com\/es\/wp-json\/wp\/v2\/categories?post=49661"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/fomatmedical.com\/es\/wp-json\/wp\/v2\/tags?post=49661"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}